Research programme: small molecule therapeutics-IFM Therapeutics

Drug Profile

Research programme: small molecule therapeutics-IFM Therapeutics

Alternative Names: NLRP antagonists - IFM therapeutics

Latest Information Update: 27 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IFM therapeutics
  • Class Anti-inflammatories; Antidementias; Antigouts; Hepatoprotectants; Small molecules
  • Mechanism of Action Immunomodulators; Inflammasome inhibitors; Inflammasome stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Gout; Inflammatory bowel diseases; Non-alcoholic steatohepatitis

Most Recent Events

  • 21 Dec 2017 Preclinical trials in Alzheimer's disease in USA (unspecified route) before December 2017
  • 21 Dec 2017 Interim pharmacodynamics data from a preclinical study in Alzheimer's disease released by IFM Therapeutics
  • 09 Aug 2017 Preclinical trials in Gout in USA before August 2017 (IFM Therapeutics pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top